Sarcopenia in Gestational Diabetes
A legfontosabb adatok
- Ki végzi
- Istituto di Neuroscienze Consiglio Nazionale delle Ricerche
- Hol
- Ausztria és Olaszország3 helyszín, 2 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Toboroz
- Résztvevők
- 200 fő, tervezett
- Kezdés
- 2025. máj. 28.
- Tervezett befejezés
- 2026. ápr.
- A vizsgálat típusa
- Megfigyeléses, 2 csoport
- A vizsgált kezelések
- Sarcopenia tests (for muscle mass, muscle function, physical performance)
- Oral Glucose Tolerance Test
- Montreal Cognitive Assessment
- A regiszteradat frissítve
- 2025. november 21.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
The trial is looking for pregnant women, with or without gestational diabetes (diabetes that starts in pregnancy). It checks for muscle loss (sarcopenia), and looks at memory and thinking.
- Életkor
- The record lists 35 years or older. The criteria also say age 35 years or older is one of several ways to join.
- Nem
- Women only.
- A betegség stádiuma
- Women must have at least one of these: age 35 years or older; BMI 25 kg/m^2 or higher; blood sugar between 5.6 and 6.9 mmol/L (101–124 mg/dL) before or early in pregnancy; a very large baby in an earlier pregnancy; gestational diabetes in an earlier pregnancy; a parent, brother, sister or child with diabetes.
- Biomarker vagy leletérték
- One possible way to join is blood sugar between 5.6 and 6.9 mmol/L (101–124 mg/dL) before or at the beginning of pregnancy.
A részvétel fő kizáró okai
- Women who have none of the conditions listed to join cannot join
- Pregnancy with twins
- A known disease that may affect muscle mass or strength
- Diseases of the brain and nerves, or mental health conditions
- Diabetes already known before, such as type 1 or type 2
A regiszter feltételei, szó szerint
Mind a 12 feltétel megnézéseKevesebb
Ki vehet részt
- At least one among the following conditions:
- Age equal to or higher than 35 years
- Body mass index (BMI) equal to or higher than 25 kg/m\^2
- Glycemia between 5.6 and 6.9 mmol/L before or at the beginning of pregnancy
- Fetal macrosomia in previous pregnancy
- GDM in previous pregnancy
- First-degree family history of diabetes
Ki nem vehet részt
- Presence of any already known disease/disorder possibly affecting muscle mass or function
- Neurological or psychiatric diseases
- Already known diabetes (e.g., type 1 or type 2 diabetes)
- Unmatching of at least one among the inclusion criteria
- Twin pregnancy
Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.
2 országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
Sarcopenia is a syndrome characterized by loss of skeletal muscle mass and strength, and physical performance deterioration. Prevalence of sarcopenia in elderly people is remarkably high (prevalence of about 25% in 60+ years people). In type 2 diabetes (T2D), sarcopenia is emerging as comorbidity of major concern. Sarcopenia, however, is not limited to elderly people, as it can develop also in younger individuals with prevalence around 9% or even higher according to some investigators. Of note, sarcopenia has been reported even in the 20-29 years interval. This interval includes women of childbearing age, thus raising the question whether sarcopenia may occur also in women with gestational diabetes (GDM) and whether this may affect pregnancy outcomes. Also, association between sarcopenia and cognitive impairment has been repeatedly reported, to the point that some authors have emphasized the importance of early sarcopenia recognition for prevention of cognitive impairment. Therefore, our main aims are:
A teljes eredeti leírásKevesebb
1. To ascertain whether sarcopenia is present in GDM and, in that case, its prevalence; 2. To identify risk factors for sarcopenia; 3. To determine sarcopenia impact on pregnancy outcomes, and cognitive function.
During pregnancy, all women will undergo oral glucose tolerance test (OGTT) for assessment of the glucometabolic condition. Several clinical variables of interest in sarcopenia will also be recorded. As regards the OGTT data, special focus will be on the assessment of insulin resistance, both at fasting and during the dynamic conditions determined by the OGTT. Notably, the special interest for insulin resistance is due to the reason that this type of metabolic alteration is known to be a risk factor for sarcopenia. In fact, all women will then undergo testing for diagnosis of sarcopenia (or presarcopenia), and all data and parameters will be analyzed to identify relationships between sarcopenia-related variables and GDM-related ones. It is worth noting that in consideration of the exacerbated insulin resistance condition often observed in GDM, the investigators expect indeed a not negligible prevalence of sarcopenia (or at least presarcopenia) in GDM women, despite the young (non-elderly) age. In addition, since insulin resistance is often present in pregnancy even in the absence of dysglycemia, the investigators do not exclude to identify some cases of sarcopenia/presarcopenia even in pregnant non-GDM women. This study will be the basis for future studies (also of interventional type), especially in women with GDM for prevention of sarcopenia and related possible pregnancy complication and adverse pregnancy outcomes, as well as for possibly contributing to mitigation of risk for T2D development in later life.
A vizsgálat 2 csoportja
- Gestational diabetes (GDM) women
Kezelés: Sarcopenia tests (for muscle mass, muscle function, physical performance), Oral Glucose Tolerance Test és Montreal Cognitive Assessment
- Pregnant women without gestational diabetes (non-GDM)
Kezelés: Sarcopenia tests (for muscle mass, muscle function, physical performance), Oral Glucose Tolerance Test és Montreal Cognitive Assessment
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- Sarcopenia in Gestational Diabetes: The SiGnal-D Study
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 15.
- Publikációk
- A regiszteradat frissítve
- 2025. november 21.